Category Archives: pharmaceuticals
December 21, 2018 | FAH Policy Blog Team
Today, the FAH commented on the Administration’s International Pricing Index Model for Medicare Part B Drugs Advance Notice of Proposed Rulemaking (ANPRM). The ANPRM signaled the Administration’s interest in testing an Innovation Center model which would dramatically change the manner in which Part B drugs are priced, acquired and paid for in the Medicare program.
November 13, 2018 | FAH Policy Blog Team
Category: Medicare, Pharmaceuticals
The Federation of American Hospitals joined 16 other groups in sending a letter to Congressional leaders today urging them to preserve the actions taken in the Bipartisan Budget Act (BBA) of 2018 to protect seniors and taxpayers from out-of-control drug prices during the upcoming lame duck session of Congress.
October 25, 2018 | Chip Kahn
Category: Financing, Medicare, Pharmaceuticals
We agree with the President that it is time to reduce the drug tab for Americans, but actions need to be focused on the real culprit - manufacturers’ prices - not the frontline hospitals and physicians who administer and prescribe those medicines. We look forward to examining the details and fine print of the Administration’s proposals.
September 24, 2018 | FAH Policy Blog Team
Category: Financing, Pharmaceuticals, Quality
This afternoon FAH filed comments with CMS regarding the 2019 Hospital Outpatient Prospective Payment System (OPPS) proposed rule.
- Public Charge Rule Could Have Chilling Effect on Access to Care
- REPORT: A Medicare Public Option Puts Majority of Rural Hospitals at Risk
- In the News – FAH’s Study on Modernizing the HCAHPS Patient Experience Survey
- Joint Statement from National Hospitals Associations on Proposed CY 2020 OPPS Rule